参考文献/References:
[1]魏秋良,蔡珊珊.中晚期原发性肝癌TACE介入微创治疗疗效和对肝功能影响观察[J].中华肿瘤防治杂志,2018,25(18):1314-1317.[2]Gholamrezanezhad A,Mirpour S,Geschwind JF,et al.Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model[J].Eur Radiol,2016,26(10):3474-3482.[3]Luz JH,Luz PM,Martin HS,et al.DEB TACE for Intermediate and advanced HCC-Initial Experience in a Brazilian Cancer Center[J].Cancer Imaging,2017,17(1):5.[4]周虹,张婧.DSCT双能量扫描成像对肝癌TACE术后碘油沉积缺损区监测分析[J].医学影像学杂志,2023,33(1):157-160.[5]Young S,Craig P,Golzarian J.Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques[J].Eur Radiol,2019,29(6):3287-3295.[6]Luo L,Xiao Y,Zhu G,et al.Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience[J].Front Oncol,2022,12:1004652.[7]Ren Y,Liu Z,Makamure J,et al.Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression[J].Technol Cancer Res Treat,2022,21:15330338221131385.[8]Cosgrove DP,Reyes DK,Pawlik TM,et al.Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results[J].Radiology,2015,277(2):594-603.[9]Deipolyi AR,Oklu R,Al-Ansari S,et al.Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma[J].J Vasc Interv Radiol,2015,26(4):516-522.[10]张发林,雍昉.应用空白微球行TACE治疗肝癌临床疗效分析[J].中华肝脏外科手术学电子杂志,2020,9(4).339-342.[11]徐微尘.鸦胆子油乳与顺铂联合吡柔比星介入治疗原发性肝癌的疗效观察[J].中国医院用药评价与分析,2015,15(8):1029-1031.[12]薛建章,陈良峰,廖凌峰,等.肝动脉栓塞化疗联合冷循环微波消融治疗肝癌的临床疗效观察[J].中华物理医学与康复杂志,2019,41(6):458-460.[13]Yang Z,Chen G,Cui Y,et al.The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study[J].Cancer Biol Ther,2019,20(3):321-327.[14]Lu W,Jin XL,Yang C,et al.Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial[J].Cancer Biol Ther,2017,18(6):433-438.[15]Chen S,Yu W,Zhang K,et al.Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma[J].BMC Cancer,2018,18(1):1131.[16]Kan X,Liang B,Zhou G,et al.Transarterial Chemoembolization Combined WithApatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis[J].Front Oncol,2020,10:970.[17]杜品清,刘云国,王东,等.载药微球经导管肝动脉化疗栓塞术治疗原发性肝癌患者的疗效及对血清胎盘生长因子、异常凝血酶原水平的影响[J].癌症进展,2020,18(13).1358-1362.[18]Malagari K,Kiakidis T,Pomoni M,et al.Pharmacokinetics,Safety,and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma[J].Cardiovasc Intervent Radiol,2016,39(10):1379-1391. [19]Urbano J,Echevarria-Uraga JJ,Ciampi-Dopazo JJ,et al.Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma[J].Eur J Radiol,2020,126:108966.[20]Huo YR,Xiang H,Chan MV,et al.Survival,tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterialchemoembolisation for hepatocellular carcinoma[J].J Med Imaging Radiat Oncol,2019,63(6):802-811.[21]Kang YJ,Lee BC,Kim JK,et al.Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma[J].Cardiovasc Intervent Radiol,2020,43(1):55-64.[22]Mikhail AS,Negussie AH,Mauda-Havakuk M,et al.Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications[J].Expert Opin Drug Deliv,2021,18(3):383-398.[23]de Baere T,Guiu B,Ronot M,et al.Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry[J].Cancers (Basel),2020,12(11):3405.[24]袁红纲,龙兵,董自强,等.吡柔比星联合顺铂膀胱灌注预防膀胱癌复发的诊治体会[J].现代肿瘤医学,2015,23(6):835-836.[25]李欣依,王其美,邓湘生,等.经肝动脉灌注鸦胆子油乳注射液联合碘油栓塞治疗中晚期原发性肝癌的临床研究[J].湖南中医杂志,2020,36(8):5-7,17.[26]邢泽宇,甄艳华,龚正,等.CalliSpheres载药栓塞微球治疗中晚期肝癌的短期效果与安全性[J].肝胆胰外科杂志,2022,34(12):747-751.[27]徐伟,吴福林,陈暑波,等.奥沙利铂、替吉奥化疗联合仑伐替尼治疗老年晚期肝癌效果及对血清肿瘤标志物的影响[J].中国老年学杂志,2022,42(3):563-565.[28]王忠,刘启榆,杨伟,等.国产CalliSpheres载药微球DEB-TACE治疗无法手术肝癌的临床价值[J].肝脏,2019,24(7):767-770.